ES2894963T8 - Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn - Google Patents
Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de CrohnInfo
- Publication number
- ES2894963T8 ES2894963T8 ES18201967T ES18201967T ES2894963T8 ES 2894963 T8 ES2894963 T8 ES 2894963T8 ES 18201967 T ES18201967 T ES 18201967T ES 18201967 T ES18201967 T ES 18201967T ES 2894963 T8 ES2894963 T8 ES 2894963T8
- Authority
- ES
- Spain
- Prior art keywords
- tnfsf15
- crohn
- disease
- variants associated
- dcr3 variants
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361824932P | 2013-05-17 | 2013-05-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2894963T3 ES2894963T3 (es) | 2022-02-16 |
ES2894963T8 true ES2894963T8 (es) | 2022-02-24 |
Family
ID=51899024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES18201967T Active ES2894963T3 (es) | 2013-05-17 | 2014-05-16 | Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn |
Country Status (7)
Country | Link |
---|---|
US (3) | US20160090629A1 (es) |
EP (3) | EP3988673A3 (es) |
JP (4) | JP6482533B2 (es) |
KR (3) | KR20210107176A (es) |
CN (1) | CN105358713B (es) |
ES (1) | ES2894963T3 (es) |
WO (1) | WO2014186750A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
CN112870368A (zh) | 2013-03-27 | 2021-06-01 | 西达-赛奈医疗中心 | 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症 |
EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
CA2994719A1 (en) | 2015-08-21 | 2017-03-02 | The Children's Hospital Of Philadelphia | Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene |
KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
KR20240095363A (ko) * | 2016-05-20 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
US20220112558A1 (en) * | 2018-09-07 | 2022-04-14 | The Children's Hospital Of Philadelphia | Compositions and methods for the diagnosis and treatment of lymphatic system disorders |
CA3140029A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
CN114450301A (zh) * | 2019-09-13 | 2022-05-06 | 协和麒麟株式会社 | DcR3变体 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
WO2009052512A2 (en) * | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
EP2257643B1 (en) * | 2008-02-19 | 2015-04-08 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
US20120073585A1 (en) * | 2009-04-08 | 2012-03-29 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
EP2960342A1 (en) * | 2009-04-14 | 2015-12-30 | Nestec S.A. | Inflammatory bowel disease prognostics |
AU2012259312A1 (en) * | 2011-05-20 | 2013-12-12 | Government Of The United States, As Represented By The Secretary Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
-
2014
- 2014-05-16 WO PCT/US2014/038468 patent/WO2014186750A2/en active Application Filing
- 2014-05-16 KR KR1020217026836A patent/KR20210107176A/ko not_active IP Right Cessation
- 2014-05-16 CN CN201480038133.6A patent/CN105358713B/zh active Active
- 2014-05-16 KR KR1020157034355A patent/KR102295125B1/ko active IP Right Grant
- 2014-05-16 US US14/890,712 patent/US20160090629A1/en not_active Abandoned
- 2014-05-16 EP EP21193676.0A patent/EP3988673A3/en active Pending
- 2014-05-16 JP JP2016514143A patent/JP6482533B2/ja active Active
- 2014-05-16 ES ES18201967T patent/ES2894963T3/es active Active
- 2014-05-16 KR KR1020237020524A patent/KR20230093538A/ko not_active Application Discontinuation
- 2014-05-16 EP EP18201967.9A patent/EP3498867B1/en active Active
- 2014-05-16 EP EP14797214.5A patent/EP2997165A4/en not_active Withdrawn
-
2018
- 2018-04-05 US US15/946,632 patent/US20180230543A1/en not_active Abandoned
- 2018-06-29 JP JP2018124311A patent/JP2018148931A/ja not_active Withdrawn
-
2020
- 2020-06-03 JP JP2020096798A patent/JP2020127437A/ja not_active Withdrawn
-
2021
- 2021-08-02 US US17/392,098 patent/US20210371931A1/en active Pending
-
2022
- 2022-06-09 JP JP2022093628A patent/JP2022111329A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210107176A (ko) | 2021-08-31 |
EP3498867A1 (en) | 2019-06-19 |
US20210371931A1 (en) | 2021-12-02 |
KR20160009582A (ko) | 2016-01-26 |
JP2022111329A (ja) | 2022-07-29 |
EP2997165A2 (en) | 2016-03-23 |
EP3988673A3 (en) | 2022-08-03 |
JP6482533B2 (ja) | 2019-03-13 |
JP2018148931A (ja) | 2018-09-27 |
EP2997165A4 (en) | 2017-03-08 |
WO2014186750A2 (en) | 2014-11-20 |
KR102295125B1 (ko) | 2021-08-31 |
US20180230543A1 (en) | 2018-08-16 |
CN105358713A (zh) | 2016-02-24 |
CN105358713B (zh) | 2020-02-28 |
JP2016526875A (ja) | 2016-09-08 |
WO2014186750A3 (en) | 2015-01-08 |
ES2894963T3 (es) | 2022-02-16 |
US20160090629A1 (en) | 2016-03-31 |
KR20230093538A (ko) | 2023-06-27 |
EP3498867B1 (en) | 2021-09-29 |
JP2020127437A (ja) | 2020-08-27 |
EP3988673A2 (en) | 2022-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264385B (en) | Newcastle disease viruses and their use | |
ES2894963T8 (es) | Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn | |
UA29014S (uk) | Комп'ютер | |
ZA201602227B (en) | Recombinant marek's disease viruses and uses thereof | |
FR3004739B3 (fr) | Ensemble d'ancrage | |
EP3006431A4 (en) | TIZOXANID CARBAMATE AND PHARMACEUTICAL USE THEREOF | |
HK1216994A1 (zh) | 減少自身免疫性疾病的風險 | |
FR3004424B1 (fr) | Marchepied amovible d'aeronef, et aeronef | |
FR3005989B1 (fr) | Turbopropulseur d'aeronef | |
FR3009885B3 (fr) | Agencement d'enroulement | |
ES1094985Y (es) | Mini-moto infantil | |
UA27219S (uk) | Форматор-вулканізатор 75" та 88" | |
UA27795S (uk) | Ковдра стьобана | |
UA26852S (uk) | Емблема «система здоров'я нації» | |
UA29813S (uk) | М'ясорубка | |
ES1092430Y (es) | "Anafe paellero" | |
UA27582S (uk) | Лист ресори | |
UA27968S (uk) | Вивіска «риба» | |
UA27575S (uk) | Логотип «живая еда» | |
ES1097881Y (es) | Delantal con sujeción de fácil colocación | |
GB201309509D0 (en) | Diagnostic marker for crohn's disease | |
ES1090460Y (es) | Pieza para contruccion de estructuras y parques infantiles. | |
UA28359S (uk) | Вагон трамвайний t5l64 «електрон» | |
ES1091609Y (es) | "gemelo" | |
UA27078S (uk) | Банкетка «02» |